12:00 AM
Nov 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NovoMix 30: Post-marketing study data

Data from an open-label, post-marketing study in 708 patients with suboptimal glycated HbA1c levels while on metformin and sulfonylurea showed that there was no significant difference in median glycated HbA1c levels for patients receiving Novomix 30 biphasic insulin aspart (7.1%), NovoRapid prandial insulin aspart (6.8%) or Levemir basal...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >